Lymphödem, Inflammation und neue Therapieansätze

Zusammenfassung

Der fehlende Abtransport eiweißreicher interstitieller Flüssigkeit führt zu den bekannten klinischen Zeichen der Lymphödems an der Haut, die im Wesentlichen durch eine Fibrosierung ausgelöst werden. Bisher basiert die Therapie auf der mechanischen Anregung des Lymphtransports durch die komplexe physikalische Entstauung (KPE) oder operativen Maßnahmen, um das Ödem zu reduzieren. Der komplexe Ablauf der Entzündungsvorgänge im Gewebe wurde in den vergangenen Jahren untersucht und zeigt die zentrale Bedeutung von T-Lymphozyten, Makrophagen, LTB4 und diversen Zytokinen. Ausgehend von diesen Erkenntnissen gibt es Erfolg versprechende Therapieansätze mit Ketoprofen, Hydroxytyrosol und weiteren Immunmodulatoren.

Abstract

Insufficient removal of protein rich interstitial fluid leads to typical changes of the skin, which is caused by fibrosis. Treatment of lymphedema consists basically in mechanic enhancement of the lymph transport with complex decongestive therapy or surgery. In the past years research on inflammation in lymphedema tissue demonstrated the important role of T-lymphocytes, macrophages, LTB4 and some cytokines. Regarding these findings we have new therapeutic aspects with ketoprofen, hydroxytyrosol and other immune modulators.

Schlüsselwörter

Lymphödem - Entzündung - T-Lymphozyten - Makrophagen - LTB4 - IL-6 - Ketoprofen - Hydroxytyrosol

Key words

lymphoedema - inflammation - t-lymphocytes - macrophages - LTB4 - IL-6 - ketoprofen - hydroxytyrosol

Publication History

Article published online:
04 March 2021

• Literatur

• 1 Gjorup CA, Groenvold M, Hendel HW. et al. Health-related quality of life in melanoma patients: impact of melanoma-related limb lymphoedema. Eur J Cancer 2017; 85: 122-132 https://doi.org/10.1016/j.ejca.2017.07.052
• 2 Kataru RP, Wiser I, Baik JE. et al. Fibrosis and secondary lymphedema: chicken or egg?. Translational Research 2019; 209: 6876
• 3 Ly CL, Kataru RP, Mehrara BJ. Inflammatory manifestations of lymphedema. Int J Mol Sci 2017; 18 DOI: 10.3390/ijms18010171.
• 4 Ly CL, Nores GDG, Kataru RP. et al. T helper 2 differentiation is necessary for development of lymphedema. Transl Res 2019; 206: 57-70 https://doi.org/10.1016/j.trsl.2018.12.003
• 5 Karlsen TV, Karkkainen MJ, Alitalo K. et al. Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema. J Physiol 2006; 574: 583-596
• 6 Cuzzone DA, Weitman ES, Albano NJ. et al. IL-6 regulates adipose deposition and homeostasis in lymphedema. Am J Physiol Heart Circ Physiol 2014; 306: H1426-H1434
• 7 Liao S, Cheng G, Conner DA. et al. Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci USA 2011; 108: 18784-18789
• 8 Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol 2006; 4: 217-228
• 9 Tian W, Rockson SG, Jiang X. et al Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Transl Med 2017; 9: eaal3920 . doi:10.1126/scitranslmed.aal3920
• 10 Gordon K, Schulte D, Brice G. et al. Mutation in vascular endothelial growth factor-c, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema. Circ Res 2013; 112: 956-960 https://doi.org/10.1161/CIRCRESAHA.113.300350
• 11 Jiang X, Nicolls MR, Tian W. et al. Lymphatic dysfunction, leukotrienes, and lymphedema. Annu Rev Physiol 2018; 80: 49-70 https://doi.org/10.1146/annurev-physiol-022516-034008
• 12 Avraham T, Zampell JC, Yan A. et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J 2013; 27: 1114-1126 https://doi.org/10.1096/fj.12-222695
• 13 Savetsky IL, Ghanta S, Gardenier JC. et al. Th2 cytokines inhibit lymphangiogenesis. PLoS One 2015; 10: e0126908 https://doi.org/10.1371/journal.pone.0126908
• 14 Zampell JC, Yan A, Elhadad S. et al. CD4+ cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis. PLoS One 2012; 7: e49940 https://doi.org/10.1371/journal.pone.0049940
• 15 Rockson SG, Tian W, Jiang X. et al. Pilot studies demonastrate the potential benefits of anti-inflammatory therapy in human lymphedema. JCI insight 2018; DOI: 10.1172/jci.insight.123775.
• 16 Bertelli M, Kiani AK, Paolacci S. et al. Molecular pathways involved in lymphedema: Hydroxytyrosol as a candidate natural compound for trating the effects of lymph accumulation. Journal of Biotechnology 2020; 308: 82-86
• 17 Van, Y-Vu Robert, Wald G, Lu C et al. The Effect of Topical Tacrolimus on Pedicled Flap Survival. Ann Plast Surg 2020; 85 (Suppl. 01) S118-S121 DOI: 10.1097/SAP.000000000000233.